Background: The study objective was to evaluate long-term safety and effectiveness of
dabigatran 110 mg and 150 mg twice daily (bid) in patients with nonvalvular atrial fibrillation …

Background Dabigatran, an oral direct thrombin inhibitor, possesses several advantages
over warfarin that can in principle simplify the management of stroke prevention in atrial …

The use of novel anticoagulants such as dabigatran are increasing. Despite increased risks
of intracerebral haemorrhage with warfarin among Asians, there is little published data on …

抄録< jats: title> summary</jats: title>< jats: p> The effectiveness and safety of dabigatran for
stroke prevention in atrial fibrillation (SPAF) demonstrated in RE-LY needs to be confirmed …

Background The effectiveness and safety of dabigatran etexilate (DE) have not been
elucidated thoroughly in clinical practice for Japanese patients with non-valvular atrial …

Objective: This analysis was performed to evaluate the efficacy in stroke prevention and
safety of dabigatran in Chinese nonvalvular atrial fibrillation (NVAF) patients enrolled in RE …

The purpose of this study is to provide detailed data on treatment persistence and clinical
outcomes in Chinese patients with nonvalvular atrial fibrillation (NVAF). A single-center …

Background There is little evidence of the efficacy and safety of dabigatran in Japanese
patients with non‐valvular atrial fibrillation (NVAF). Methods and Results We evaluated 300 …

Background: RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an
international multicenter study (18,113 patients from 967 centers in 44 countries) that …

Background: Dabigatran was shown effective for stroke prevention in atrial fibrillation (AF) in
RE-LY; and RELY-ABLE provided additional follow-up of dabigatran. Combining these two …